阿尔茨海默病治疗中相关雌激素信号途径的研究进展  

Research Progress of Estrogen Signal Pathway in Alzheimer's Disease

作　　者：刘杨[1] 沈丽霞[1] 

机构地区：[1]河北北方学院药学系

出　　处：《神经药理学报》2015年第4期43-54,共12页Acta Neuropharmacologica

基　　金：河北省自然科学基金资助项目(No.H2012405016);河北省高等学校科学技术研究项目(No.ZD2015131)

摘　　要：阿尔茨海默病(Alzheimer’s disease,AD)是一种常见的神经退行性疾病,主要表现为进行性认知功能障碍和记忆力减退。大量临床和流行病学证据表明女性与男性相比有较高的发病率,表明女性更年期雌激素水平下降可能诱发AD。最近的研究提出雌激素可以直接减少细胞外β-淀粉样蛋白(β-amyloid protein,Aβ)大量聚集形成的老年斑(senile plaque,SP)和tau蛋白过度磷酸化形成的神经原纤维缠结的生成。大量实验证实雌激素具有神经保护作用,但绝经后女性的临床试验表明雌激素对AD的影响并不明显,这可能与雌激素受体选择性相关。该文就近年来雌激素及其ERα或ERβ受体与AD的研究做一综述,进一步讨论雌激素受体选择性配体作为AD治疗中安全、有效的靶点。Alzheimer’s disease(AD) is a common neurodegenerative disease,and main symptoms are progressive cognitive dysfunction and memory deterioration. Numerous clinical and epidemiological studies show that there is a gender difference in the incidence ofAD,women are more likely to develop AD post-menopause,which indicated that the lack of estrogen is a risk factor of AD. Recent research has proposed estrogen can directly reduce the accumulation of senile plaque and neurofibrillary tangles. Studies have shown that estrogen may have neuroprotective effects,while clinical trials of women post-menopausal show no obvious effects of estrogen on AD. The discrepancies may relate to the selectivity of estrogen receptors. This review will make a brief summary on AD related estrogen and estrogen receptors such as ER alpha or ER beta subtype,further discussing selective ligands of estrogen receptors to provide a safe and effective treatment to AD.

关 键 词：雌激素 雌激素受体 阿尔茨海默病 

分 类 号：R964[医药卫生—药理学]